MA55735A - Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23 - Google Patents

Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23

Info

Publication number
MA55735A
MA55735A MA055735A MA55735A MA55735A MA 55735 A MA55735 A MA 55735A MA 055735 A MA055735 A MA 055735A MA 55735 A MA55735 A MA 55735A MA 55735 A MA55735 A MA 55735A
Authority
MA
Morocco
Prior art keywords
inhibitor
polytherapy
inhibitor based
based polytherapy
Prior art date
Application number
MA055735A
Other languages
English (en)
Inventor
Michele Luise Gerber
Heath Michael Guay
Neil Bradford Lineberry
Jorge Rodrigo Mora
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA55735A publication Critical patent/MA55735A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055735A 2019-04-17 2020-04-17 Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23 MA55735A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962835349P 2019-04-17 2019-04-17

Publications (1)

Publication Number Publication Date
MA55735A true MA55735A (fr) 2022-02-23

Family

ID=72837950

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055735A MA55735A (fr) 2019-04-17 2020-04-17 Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23

Country Status (5)

Country Link
US (1) US20230096620A1 (fr)
EP (1) EP3956358A4 (fr)
JP (2) JP7778567B2 (fr)
MA (1) MA55735A (fr)
WO (1) WO2020215019A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240103043A (ko) * 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US10040855B2 (en) * 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CN107454905B (zh) * 2015-03-31 2023-04-28 索里索制药公司 多肽
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
WO2017106595A1 (fr) * 2015-12-18 2017-06-22 Sciadonics, Inc. Formulations lipidiques contenant des acides gras bioactifs et un agent anti-inflammatoire non de type acide gras
MA44864A (fr) * 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
CA3045931A1 (fr) * 2016-12-14 2018-06-21 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de l'integrine
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
BR112019022268A2 (pt) * 2017-04-28 2020-05-19 Millennium Pharmaceuticals, Inc. método para o tratamento de distúrbios pediátricos
US20230033021A1 (en) * 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
JP2022529929A (ja) 2022-06-27
EP3956358A4 (fr) 2023-01-25
JP2025169256A (ja) 2025-11-12
EP3956358A1 (fr) 2022-02-23
US20230096620A1 (en) 2023-03-30
JP7778567B2 (ja) 2025-12-02
WO2020215019A1 (fr) 2020-10-22

Similar Documents

Publication Publication Date Title
EP3890789A4 (fr) Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
EP3402500A4 (fr) Polythérapie à base d'un virus oncolytique et d'un inhibiteur de point de contrôle
EP3819300A4 (fr) Composition thérapeutique à base de biomarqueurs
UA42295S (uk) Комп'ютер
UA42369S (uk) Комп'ютер
EP3463405A4 (fr) Polythérapie à base d'adénovirus et d'immunomodulateurs
EP3512548A4 (fr) Polythérapie à base d'un anticorps et d'un inhibiteur de point de contrôle
EP4004677A4 (fr) Appareil d'affichage
EP3441495A4 (fr) Matériau d'acier inoxydable à base d'austénite
EP3995553A4 (fr) Adhésif à base d'isocyanate
EP4004898A4 (fr) Appareil d'affichage
EP4075258A4 (fr) Appareil d'affichage
EP3359150A4 (fr) Polythérapie à l'aide d'inhibiteurs de glutaminase et agents immuno-oncologiques
EP4022596A4 (fr) Appareil d'affichage
EP3885377A4 (fr) Polymère à base d'oléfine
EP3824186A4 (fr) Compresseur à spirales
EP3867898A4 (fr) Étiquette à témoin d'intégrité
EP4006633A4 (fr) Appareil d'affichage
EP3909068A4 (fr) Inhibiteur de corrosion à base d'oxyde de hafnium
EP3982415A4 (fr) Panneau d'affichage
EP3919579A4 (fr) Composition adhésive à base d'uréthane
EP3919581A4 (fr) Composition d'agent adhésif à base d'uréthane
EP3957660A4 (fr) Polymère à base d'oléfine
EP3949444A4 (fr) Appareil d'affichage
MA55735A (fr) Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23